Research programme: kidney disorder therapeutics - Brigham and Women's Hospital/Evotec/Harvard University

Drug Profile

Research programme: kidney disorder therapeutics - Brigham and Women's Hospital/Evotec/Harvard University

Alternative Names: Acute kidney disease therapeutics - Brigham and Women's Hospital/Evotec/Harvard University; Chronic kidney disease therapeutics - Brigham and Women's Hospital/Evotec/Harvard University; CureNephron

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator Brigham and Womens Hospital; Evotec AG; Harvard University; University of Southern California
  • Developer Brigham and Womens Hospital; Evotec AG; Harvard University
  • Class
  • Mechanism of Action Cell death inhibitors; Cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Kidney disorders

Most Recent Events

  • 21 Sep 2016 Kidney disorder therapeutics licensed to Bayer
  • 16 Jul 2016 No recent reports of development identified for research development in Kidney-disorders in Germany
  • 16 Jul 2016 No recent reports of development identified for research development in Kidney-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top